Abstract
Alzheimer’s disease (AD) is a progressive neurological disease, characterised by deterioration in patient cognition, function and behaviour. No disease-modifying treatments are currently approved for use in the UK, with current practice focused on symptom management. This analysis aimed to identify cost-effective treatment profiles for a hypothetical emerging treatment (HET) in patients with mild AD from an English NHS perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
